Parkinsonmittel

  • Ulrich Schwabe
Chapter

Zusammenfassung

Die Parkinsonsche Krankheit ist eine fortschreitende neurologische Erkrankung des extrapyramidalmotorischen Systems, von der 1% der Bevölkerung über 65 Jahre betroffen ist. Ursache ist eine in ihrer Ätiologie unbekannte Degeneration von Nervenzellen in der Substantia nigra, die zu einem „striatalen“ Dopaminmangelsyndrom führt und mit einer erhöhten cholinergen Aktivität einhergeht. Die klassischen Symptome sind Akinese, Rigor und Tremor. Daneben treten zunehmend nichtmotorische Symptome wie vegetative und kognitive Störungen ins Blickfeld, die mit den derzeit verfügbaren Therapieoptionen weniger gut beeinflussbar sind (Übersicht bei Lees et al. 2009).

This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Ahlskog JE, Uitti RJ (2010): Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction? Neurology74: 1143–1148.PubMedCrossRefGoogle Scholar
  2. Anonymus (2008): Rotigotine: Parkinson’s disease: a step backward. Prescrire Int 17: 60.Google Scholar
  3. Arnold G, Kupsch A (2000): Hemmung der Catechol-O-Methyltransferase. Optimierung der dopaminergen Therapie beim idiopathischen Parkinsonsyndrom mit Entacapone. Nervenarzt 71: 78–83.PubMedCrossRefGoogle Scholar
  4. Chen JJ, Swope DM (2005): Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease. J Clin Pharmacol 45: 878–894.PubMedCrossRefGoogle Scholar
  5. Crosby NJ, Deane KH, Clarke CE (2003): Amantadine in Parkinson’s disease. Cochrane Database Syst Rev. 2003;(1):CD003468.Google Scholar
  6. Deane KH, Spieker S, Clarke CE (2004): Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson’s disease. Cochrane Database Syst Rev. 2004 Oct 18;(4): CD004554.Google Scholar
  7. Deutsche Gesellschaft für Neurologie (2008): Parkinson-Syndrome. Internet: www.dgn.org/images/stories/dgn/leitlinien/LL2008/ll08kap_009.pdf
  8. European Medicines Agency (EMA) (2004): EMEA public statement on the lifting of the suspension of the marketing authorisation for tolcapone (Tasmar). Internet: www.emea.eu.int/pdfs/human/press/pus/1185404en.pdf
  9. European Medicines Agency (EMA) (2006): Rotigotin. Europäischer öffentlicher Beurteilungsbericht (EPAR). Internet: www.emea.eu.int/humandocs/PDFs/EPAR/neupro/062606de1.pdf
  10. Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S (1999): Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 52: 1908–1910.PubMedGoogle Scholar
  11. Giladi N, Boroojerdi B, Korczyn AD, Burn DJ, Clarke CE, Schapira AH; SP513 investigators (2007): Rotigotine transdermal patch in early Parkinson‘s disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord 22: 2398–2404.PubMedCrossRefGoogle Scholar
  12. Ives NJ, Stowe RL, Marro J, Counsell C, Macleod A, Clarke CE, Gray R, Wheatley K (2004): Monoamine oxidase type B inhibitors in early Parkinson‘s disease: metaanalysis of 17 randomised trials involving 3525 patients. BMJ 329: 593–599.PubMedCrossRefGoogle Scholar
  13. Katzenschlager R, Sampaio C, Costa J, Lees A (2003): Anticholinergics for symptomatic management of Parkinson‘s disease. Cochrane Database Syst Rev. 2003;(2): CD003735.Google Scholar
  14. Koller WC, Tse W (2004): Unmet medical needs in Parkinson‘s disease. Neurology 62 (Suppl 1): S1–8.Google Scholar
  15. Lees AJ (1995): Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson’s disease. Parkinson’s Disease Research Group of the United Kingdom. BMJ 311: 1602–1607.PubMedGoogle Scholar
  16. Lees AJ, Hardy J, Revesz T (2009): Parkinson‘s disease. Lancet 373: 2055–2066.PubMedCrossRefGoogle Scholar
  17. Lees AJ, Katzenschlager R, Head J, Ben-Shlomo Y (2001): Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial. Neurology 57: 1687–1694.PubMedGoogle Scholar
  18. Mejer Nielsen B (1983): Tiapride in levodopa-induced involuntary movements. Acta Neurol Scand 67: 372–375.PubMedCrossRefGoogle Scholar
  19. Obeso JA, Rodriguez-Oroz MC, Goetz CG, Marin C, Kordower JH, Rodriguez M, Hirsch EC, Farrer M, Schapira AH, Halliday G (2010): Missing pieces in the Parkinson’s disease puzzle. Nat Med 16: 653–661.PubMedCrossRefGoogle Scholar
  20. Olanow C W, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, Langston W, Melamed E, Poewe W, Stocchi F, Tolosa E; ADAGIO Study Investigators (2009): A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N Engl J Med 361: 1268–1278.PubMedCrossRefGoogle Scholar
  21. Pahwa R, Factor SA, Lyons KE, Ondo WG, Gronseth G, Bronte-Stewart H, Hallett M, Miyasaki J, Stevens J, Weiner WJ; Quality Standards Subcommittee of the American Academy of Neurology (2006): Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66: 983–995.PubMedCrossRefGoogle Scholar
  22. Parkinson Study Group (2004): A controlled, randomized, delayed-start study of rasa-giline in early Parkinson disease. Arch Neurol 61: 561–566.CrossRefGoogle Scholar
  23. Parkinson Study Group (2005): A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62: 241–248.CrossRefGoogle Scholar
  24. Rascol O, Brooks DJ, Korczyn AD, De Deyn P P, Clarke CE, Lang AE for The 056 Study Group (2000): A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. N Engl J Med 342: 1484–1491.PubMedCrossRefGoogle Scholar
  25. Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi F, Tolosa E; LARGO study group (2005): Rasagiline as an adjunct to levodopa in patients with Parkinson‘s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 365: 947–954.PubMedCrossRefGoogle Scholar
  26. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E (2007): Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 356: 29–38.PubMedCrossRefGoogle Scholar
  27. Schapira AH (2004): Restless legs syndrome: an update on treatment options. Drugs 64: 149–158.PubMedCrossRefGoogle Scholar
  28. Scottish Intercollegiate Guidelines Network (2010): Diagnosis and pharmacological management of Parkinson’s disease. A national clinical guideline. Internet: www.sign.ac.uk/pdf/sign113.pdf
  29. Silver DE, Ruggieri S (1998): Initiating therapy for Parkinson’s disease. Neurology 50 (Suppl 6): S18–S22; discussion S44–S48.Google Scholar
  30. The Parkinson Study Group (1993): Effects of tocopherol and deprenyl on the progression of disability in early parkinson‘s disease. N Engl J Med 328: 176–183.CrossRefGoogle Scholar
  31. The Parkinson Study Group (2004): Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 61: 1044–1053.CrossRefGoogle Scholar
  32. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G (2007): Valvular heart disease and the use of dopamine agonists for Parkinson‘s disease. N Engl J Med 356: 39–46.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2010

Authors and Affiliations

  • Ulrich Schwabe
    • 1
  1. 1.Pharmakologisches Institutder Universität HeidelbergHeidelberg

Personalised recommendations